Syros Pharmaceuticals Inc
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute mye… Read more
Syros Pharmaceuticals Inc (SYRS) - Total Assets
Latest total assets as of September 2024: $85.00 Million USD
Based on the latest financial reports, Syros Pharmaceuticals Inc (SYRS) holds total assets worth $85.00 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Syros Pharmaceuticals Inc - Total Assets Trend (2014–2023)
This chart illustrates how Syros Pharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Syros Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Syros Pharmaceuticals Inc's total assets of $85.00 Million consist of 86.2% current assets and 13.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 83.0% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2023)
This chart illustrates how Syros Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Syros Pharmaceuticals Inc's current assets represent 86.2% of total assets in 2023, a decrease from 98.5% in 2014.
- Cash Position: Cash and equivalents constituted 83.0% of total assets in 2023, down from 98.2% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Syros Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Syros Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Syros Pharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Syros Pharmaceuticals Inc generates 0.06x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Syros Pharmaceuticals Inc is currently not profitable relative to its asset base.
Syros Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.25 | 4.31 | 4.87 |
| Quick Ratio | 2.25 | 4.31 | 4.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $35.54 Million | $ 94.12 Million | $ 91.00 Million |
Syros Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Syros Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.65 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -31.2% |
| Total Assets | $168.17 Million |
| Market Capitalization | $329.84K USD |
Valuation Analysis
Below Book Valuation: The market values Syros Pharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Syros Pharmaceuticals Inc's assets decreased by 31.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Syros Pharmaceuticals Inc (2014–2023)
The table below shows the annual total assets of Syros Pharmaceuticals Inc from 2014 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $168.17 Million | -31.21% |
| 2022-12-31 | $244.49 Million | +33.65% |
| 2021-12-31 | $182.94 Million | -14.22% |
| 2020-12-31 | $213.25 Million | +42.19% |
| 2019-12-31 | $149.98 Million | +40.47% |
| 2018-12-31 | $106.77 Million | +36.03% |
| 2017-12-31 | $78.49 Million | -14.05% |
| 2016-12-31 | $91.32 Million | +109.31% |
| 2015-12-31 | $43.63 Million | -29.05% |
| 2014-12-31 | $61.49 Million | -- |